Biohaven licenses IgG degrader portfolio to Ono Pharma in Asian agreement worth up to $100m in near-term payments
Biohaven grants Ono Pharma regional rights to BHV-1300 and extracellular IgG degrader programmes
Biohaven has entered a licensing agreement granting Ono Pharmaceutical rights to its extracellular IgG degrader programmes in Japan and selected Asian markets, including Phase 3 candidate BHV-1300.
The agreement includes an $80m upfront payment, a potential additional $20m milestone and royalties of approximately 20%, expanding the regional commercial opportunity for Biohaven's immunology portfolio.
Field | Content |
Alert Type | Deals |
Companies | Biohaven; Ono Pharmaceutical |
Deal Type | Exclusive regional licensing agreement |
Asset or Company | BHV-1300 and follow-on extracellular IgG degrader programmes |
Therapy Area(s) | Immunology; autoimmune diseases; Graves' disease |
Technology or Modality | Extracellular IgG degradation |
Deal Value | $80m upfront; potential additional $20m milestone; approximately 20% royalties |
Development Stage (if relevant) | BHV-1300 in Phase 3 development for Graves' disease |
Geography | Japan and selected Asian markets |
What Happened | Biohaven entered a strategic licensing agreement with Ono Pharmaceutical covering BHV-1300 and follow-on extracellular IgG degrader programmes in specified Asian territories. |
Why It Matters | The agreement provides Biohaven with near-term funding and a regional development and commercialisation partner for its extracellular IgG degradation platform. |
Supporting Context | BHV-1300 is an investigational extracellular IgG degrader being evaluated in Phase 3 clinical development for Graves' disease. |
Strategic Rationale (optional) | Ono gains regional access to Biohaven's investigational IgG degradation technology while Biohaven retains opportunities outside the licensed territories. |
Potential Impact (optional) | The partnership could support future development and commercial access to IgG degrader treatments in the licensed Asian markets, subject to successful trials and regulatory approvals. |
Key Takeaway | Biohaven's agreement with Ono combines $80m upfront funding with additional milestone and royalty opportunities for its IgG degrader portfolio. |
What to Watch (optional) | BHV-1300 Phase 3 results, regulatory submissions and regional development milestones. |
Primary Source | https://ir.biohaven.com/news-releases/news-release-details/biohaven-enters-strategic-licensing-agreement-ono-pharma |
Relevant Date | 8 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
留言